The Fox Chase–Temple University Hospital Bone Marrow Transplant Program has received internationally recognized accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT) at the University of Nebraska Medical Center.
By demonstrating compliance with the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing, and Administration, the joint program of Fox Chase Cancer Center and Temple has earned FACT accreditation for adult allogeneic and autologous hematopoietic progenitor cell transplantation, peripheral blood cellular therapy product collection, and cellular therapy product processing with minimal manipulation.
About FACT Accreditation
FACT is an internationally recognized accrediting body for hospitals and medical institutions offering stem cell transplant and indicates the accredited institution has met the most rigorous standards in every aspect of stem cell therapy. This covers the entire spectrum of stem cell therapy, from clinical care to donor management; cell collection; processing; storage; transportation; administration; and cell release.
FACT-JACIE Standards are defined by leading experts based on the latest knowledge of the field of cellular therapy transplantation. The bone marrow transplant program has been found to be in compliance with these rigorous Standards, as well as governmental regulations.
Henry C. Fung, MD
“We sought FACT accreditation because it has evolved into an all-but-necessary qualification to be accepted and competitive in the field of cellular therapy,” said Henry C. Fung, MD, Vice Chair of Hematology at Fox Chase and Director of the Fox Chase–Temple University Hospital Bone Marrow Transplant Program. “We believe FACT accreditation will make patients aware that our facility strives to achieve the highest quality care for cellular therapy.”
FACT accreditation is attained through evaluation of submitted documentation and on-site inspection to determine whether an organization is in compliance with current FACT Standards and the U.S. Food and Drug Administration’s current rules for Good Tissue Practice. ■
